{Reference Type}: Journal Article {Title}: Local antibiotics in posterior lumbar fusion procedures for neuromuscular scoliosis: a case for their use. {Author}: Ondeck NT;Ondeck MA;Bovonratwet P;Albert TJ;Grauer JN; {Journal}: Spine J {Volume}: 21 {Issue}: 4 {Year}: 04 2021 {Factor}: 4.297 {DOI}: 10.1016/j.spinee.2020.12.004 {Abstract}: Surgical site infections (SSIs) are medically devastating and financially costly complications after posterior spinal fusion (PSF) for neuromuscular scoliosis (NMS). Many strategies exist to reduce their occurrence. The efficacy of intraoperative antibiotics in the wound or bone graft is gaining in popularity, but this practice has not been well-studied in the PSF NMS population.
To assess the potential utility of intraoperative local antibiotics in patients with NMS undergoing PSF.
Retrospective review of prospectively collected data.
Pediatric patients who underwent PSF for NMS were identified from the 2016-2018 National Surgical Quality Improvement Program (NSQIP) pediatric spinal fusion datasets.
Perioperative adverse outcome variables assed included the occurrence of SSI, renal complications, and adverse hospital metrics.
Patient demographic factors, comorbidities, and the use of intraoperative antibiotics in the wound were recorded (a specifically assessed variable in the dataset). The association between the use of intraoperative antibiotics and the occurrence of adverse outcomes/infection was assessed for the entire study population and higher risk sub-populations.
In total, 1,990 patients met the inclusion criteria, of which 87% received local antibiotics. Higher risk patients were more likely to receive local antibiotics in the wound as part of their procedure. When controlling for potentially confounding factors, the use of local antibiotics was not statistically significantly associated with any of the studied adverse outcomes for the overall study population. Subgroup analysis of higher risk patient populations (≥13 levels fused, osteotomy performed, prior deformity surgery, nonasthma lung condition) revealed a significantly decreased risk of SSI in patients undergoing ≥13 level fusions (relative risk: 0.48, 95% confidence interval: 0.25-0.91).
With no increased overall risks and reduced SSIs in higher risk NMS patients undergoing PSF, the use of intrawound antibiotics appears to be supported by this dataset.